 The primary purpose of this study is to evaluate the safety and tolerability of SRT2104 2.0 g administered once daily for 28 days and to examine the effects of SRT2104 2.0 g administered once daily for 28 days on reversing vasomotor and fibrinolytic dysfunction in both type 2 diabetes mellitus patients and otherwise healthy cigarette smokers in a fed state. 